Homepage / Programme Live /

The antigen-specific immunotherapy rhGAD65 delays progression of stage 3 T1D in individual with HLA DR3-DQ2 - survival analysis of combined data from three randomized controlled trials - (P-193)

Talk details

Poster Corner 2 FRIDAY: New insulins; Adjunctive Therapies; Other Pharmacologic Agents; Novel Advances and Interventions
Novel Advances and Interventions
The antigen-specific immunotherapy rhGAD65 delays progression of stage 3 T1D in individual with HLA DR3-DQ2 - survival analysis of combined data from three randomized controlled trials (P-193)
A. LINDQVIST
07/11/2025 15:15 - 16:15 CEST